ASAH1 and Hepatic fibrosis: Pharmacologic inhibition or genetic knockout of acid ceramidase in HSC could inhibit YAP/TAZ signaling pathway activity, increase ceramides accumulation in HSCs and prevent liver fibrosis, implicating ceramide as a critical regulator of YAP/TAZ signaling and HSC activation and highlighting acid ceramidase as a therapeutic target for the treatment of fibrosis 120.